Company intelligence / Profile preview

Orbitz

Oxford, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Orbit Discovery provides peptide discovery services using proprietary bead-based and microfluidic screening platforms. Their technology enables the identification of functional agonists/antagonists to both soluble and membrane-bound targets (especially GPCRs). They support clients' drug discovery pipelines, but do not disclose specific clinical assets.

Therapeutic areas: OncologyRare Diseases
Modalities: PeptidesPeptide-drug conjugateSmall molecule
Industry: Drug Discovery Services

Partnerships

Oxford Sciences Innovation (investor/partner)Bio/pharma customers (undisclosed)

Beyond the preview

Go deeper on Orbitz.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orbitz.

Explore the full profile